Skip to content
The proposed updated European Union General Pharmaceutical Legislation offers some opportunities but also creates some new threats for biotech—and when it becomes law in […]
Proposed EU Pharma Law features good intentions and bad ideas, says BIO-Europe panel Read More »
As weakening investment plagues small, innovative biotechs on both sides of the Atlantic, one bright spot in providing funding is acquisitions—though even that vital
M&A activity a bright spot in funding for biotech, expert tells 2023 BIO-Europe Read More »
A bill to incentivize production of low-carbon biofuels by ensuring that the environmental benefits of these fuels are measured accurately when assessing tax credits
Bill seeks accurate measures of how well biofuels cut carbon emissions Read More »
Federal Trade Commission (FTC) proposals for new rules to permit more aggressive opposition to mergers would interfere with the economic ecosystem that is essential
FTC plans for aggressive merger enforcement threaten biotech innovation, BIO says Read More »
Legislation to encourage innovation and protect patent holders should not be distorted into instruments for drug price controls, a high-profile group of former judges,
Top legal experts: Laws protecting IP aren’t tools for drug price controls Read More »
Generated by our own internal defenses, sepsis claims 350,000 adult lives each year in the United States and is the most costly condition behind
Battling sepsis and superbugs requires awareness and policy Read More »
Drug price controls in the Inflation Reduction Act (IRA) harm the development of new drugs, according to Sept. 20 testimony in Congress from John
BIO Vice Chair John F. Crowley to Congress: IRA reduces access to innovative drugs Read More »
Horseshoe crabs have been living in the ocean for almost half a billion years, surviving five mass extinctions. However, their use in lab tests
Drug makers promote new toxin testing technology to spare horseshoe crabs Read More »
The Biotechnology Innovation Organization (BIO) filed an amicus brief opposing the Federal Trade Commission (FTC) lawsuit to block Amgen’s acquisition of Horizon, arguing that
BIO to file amicus brief opposing FTC interference in vital biotech merger activity Read More »
The challenge of preventing pharmacy benefit managers (PBMs) from driving up drug prices was front and center on Capitol Hill this week. Bipartisan legislation
Congress puts PBMs in the spotlight during a busy week on Capitol Hill Read More »
